S'abonner

Clinical phenotype and complications of large vessel giant cell arteritis: A systematic review and meta-analysis - 21/06/23

Doi : 10.1016/j.jbspin.2023.105558 
Suellen Anne Lyne a, b, , c , Carlee Ruediger a, b, Susan Lester a, b, Gursimran Kaur d, Lisa Stamp d, e, Ernst Michael Shanahan c, f, Catherine Louise Hill a, b, g
a University of Adelaide, North Terrace, Adelaide 5005, South Australia, Australia 
b Rheumatology Department, Level 5 the Tower Block, The Queen Elizabeth Hospital, 28, Woodville road, Woodville 5011, South Australia, Australia 
c Rheumatology Department, Flinders Medical Centre, Flinders Drive, Bedford Park 5042, South Australia, Australia 
d Rheumatology Department, Christchurch Hospital, 2, Riccarton avenue, Christchurch Central City, 4710 Christchurch, New Zealand 
e University of Otago, Christchurch Hospital, 2, Riccarton avenue, Christchurch Central City, 4710 Christchurch, New Zealand 
f Flinders University, Sturt Road, Bedford Park 5042, South Australia, Australia 
g Rheumatology Department, Royal Adelaide Hospital, Port Road, Adelaide 5000, South Australia, Australia 

Corresponding author.

Highlights

Large vessel giant cell arteritis forms a distinct subset of disease.
Patients are often younger and have non-specific presenting symptoms.
The diverse clinical spectrum limits usefulness of standardised diagnostic criteria.
Identification of large vessel disease may ameliorate potential adverse outcomes.

Le texte complet de cet article est disponible en PDF.

Abstract

Background

Giant Cell Arteritis (GCA) is a heterogenous systemic granulomatous vasculitis involving the aorta and any of its major tributaries. Despite increased awareness of large vessel (LV) involvement, studies reporting incidence, clinical characteristics and complications of large-vessel GCA (LV-GCA) show conflicting results due to inconsistent disease definitions, differences in study methodologies and the broad spectrum of clinical presentations. The aim of this systematic literature review was to better define LV-GCA based on the available literature and identify distinguishing characteristics that may differentiate LV-GCA patients from those with limited cranial disease.

Methods

Published studies indexed in MEDLINE and EMBASE were searched from database inception to 7th May 2021. Studies were included if they presented cohort or cross-sectional data on a minimum of 25 patients with LV-GCA. Control groups were included if data was available on patients with limited cranial GCA (C-GCA). Data was quantitatively synthesised with application of a random effects meta-regression model, using Stata.

Results

The search yielded 3488 studies, of which 46 were included. Diagnostic criteria for LV-GCA differed between papers, but was typically dependent on imaging or histopathology. Patients with LV-GCA were generally younger at diagnosis compared to C-GCA patients (mean age difference –4.53 years), had longer delay to diagnosis (mean difference 3.03 months) and lower rates of positive temporal artery biopsy (OR: 0.52 [95% CI: 0.3, 0.91]). Fewer LV-GCA patients presented with cranial manifestations and only 53% met the 1990 ACR Classification Criteria for GCA. Vasculitis was detected most commonly in the thoracic aorta, followed by the subclavian, brachiocephalic trunk and axillary arteries. The mean cumulative prednisolone dose at 12-months was 6056.5mg for LV-GCA patients, relapse rates were similar between LV- and C-GCA patients, and 12% of deaths in LV-GCA patients could be directly attributed to an LV complication.

Conclusion

Patients with LV-GCA have distinct disease features when compared to C-GCA, and this has implications on diagnosis, treatment strategies and surveillance of long-term sequalae.

Le texte complet de cet article est disponible en PDF.

Keywords : Giant cell arteritis, Large vessel vasculitis, Extra-cranial, Systematic literature review, Meta-analysis


Plan


© 2023  Société française de rhumatologie. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 90 - N° 4

Article 105558- juillet 2023 Retour au numéro
Article précédent Article précédent
  • The future of polymyalgia rheumatica research: What can we learn from rheumatoid arthritis?
  • Lien Moreel, Michaël Doumen, Albrecht Betrains, Daniel Blockmans, Patrick Verschueren, Steven Vanderschueren
| Article suivant Article suivant
  • Preserving bone in cancers of the elderly: A necessity
  • Nicolas Bertrand, Marie Bridoux, Cédric Gaxatte, Henry Abi Rached, Anthony Turpin, Jean-Guillaume Letarouilly, Marie-Hélène Vieillard

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.